| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 36,626 | 35,021 | 32,496 | 42,327 |
| Short-term marketable securities | 67,913 | 78,103 | 84,197 | 83,080 |
| Prepaid expenses and other current assets | 3,177 | 3,280 | 2,787 | 1,789 |
| Total current assets | 107,716 | 116,404 | 119,480 | 127,196 |
| Long-term marketable securities | NaN | 0 | 8,806 | 10,059 |
| Operating lease right-of-use assets | 39 | 78 | 115 | 152 |
| Total assets | 107,755 | 116,482 | 128,401 | 137,407 |
| Accounts payable | 2,303 | 1,309 | 4,243 | 1,921 |
| Accrued expenses and other current liabilities | 2,955 | 3,714 | 4,788 | 5,174 |
| Operating lease liabilities | 39 | 78 | 115 | 152 |
| Total current liabilities | 5,297 | 5,101 | 9,146 | 7,247 |
| Common stock-Common Class A | 3 | 3 | 3 | 3 |
| Common stock-Common Class B | 0 | 0 | 0 | 0 |
| Additional paid-in capital | 459,446 | 457,607 | 455,916 | 453,954 |
| Accumulated deficit | -356,999 | -346,349 | -336,781 | -323,873 |
| Accumulated other comprehensive income | 8 | 120 | 117 | 76 |
| Total stockholders' equity | 102,458 | 111,381 | 119,255 | 130,160 |
| Total liabilities and stockholders' equity | 107,755 | 116,482 | 128,401 | 137,407 |
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)